This Day On The Street
Continue to site
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Pivotal Phase III Data In Polycythemia Vera Show That Jakafi® (ruxolitinib) Achieved Superior Disease Control Compared To Best Available Therapies

Incyte Corporation (Nasdaq: INCY) today announced results from the RESPONSE trial, the first pivotal Phase III study evaluating a JAK1/JAK2 inhibitor for the treatment of polycythemia vera (PV). Ruxolitinib, compared to best available therapy (BAT), significantly improved hematocrit control (red blood cell volume) without the need for phlebotomy (a procedure to remove blood from the body to reduce the concentration of red blood cells) and reduced spleen size in patients with uncontrolled PV -- those who are resistant to or intolerant of hydroxyurea (HU). Findings from the RESPONSE study are being presented in an oral presentation at the 50th Annual Meeting of the American Society of Clinical Oncology in Chicago.

“Patients with advanced PV whose disease is not well-managed with existing therapies are at increased risk for thrombosis and suffer from multiple debilitating symptoms,” stated Srdan Verstovsek, M.D., Ph.D., Professor, Department of Leukemia, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center. “Data from the RESPONSE trial demonstrated that treatment with ruxolitinib can consistently control hematocrit, reduce spleen size, and improve symptoms such as fatigue and itching. Importantly, there appears to be a lower rate of thrombosis in the ruxolitinib arm compared to best available therapy.”

Seventy-seven percent of ruxolitinib-treated patients versus 20 percent on BAT achieved at least one component of the primary endpoint: hematocrit control from week 8 to 32 and/or at least a 35 percent reduction in spleen volume. A greater proportion of patients treated with ruxolitinib achieved the composite primary endpoint compared to BAT (21 percent vs 1 percent, respectively; P< .0001); 91 percent of patients in the ruxolitinib group achieving this endpoint maintained their response at week 48.

A greater proportion of patients in the ruxolitinib treatment arm had complete hematologic remission, a key secondary endpoint, when compared to the BAT arm (24 percent compared to 9 percent, P=.003). Patients treated with ruxolitinib also experienced meaningful improvements in PV-related symptoms: 49 percent, compared to 5 percent treated with BAT, had a 50 percent or greater improvement in symptom score at week 32 as measured by the 14-item MPN-SAF (Myeloproliferative Neoplasm Symptom Assessment Form). At week 32, one patient in the ruxolitinib group and six in the BAT group had a thromboembolic event.

At a median follow-up of 81 weeks, 85 percent of patients in the ruxolitinib arm were still receiving treatment. Because most patients in the BAT group crossed over to receive ruxolitinib therapy at week 32, adverse events were evaluated at this time when exposure between groups was similar. The most common non-hematologic adverse events of any grade in the ruxolitinib group compared to the BAT group were headache (16.4 percent vs 18.9 percent), diarrhea (14.5 percent vs 7.2 percent), fatigue (14.5 percent vs 15.3 percent), and pruritus (13.6 percent vs 22.5 percent). Based on laboratory assessments, the rates of new or worsening grade 3 or 4 anemia and thrombocytopenia in the ruxolitinib group versus the BAT group were 1.8 percent vs 0 percent and 5.5 percent vs 3.6 percent, respectively.

1 of 4

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Options Profits

Our options trading pros provide over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • Actionable options commentary and news
  • Real-time trading community
SYM TRADE IT LAST %CHG

Markets

DOW 18,162.99 +121.45 0.67%
S&P 500 2,123.48 +19.28 0.92%
NASDAQ 5,106.5930 +73.8420 1.47%

Partners Compare Online Brokers

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs